Cell Biotech Co

Cell Biotech Co Equity Ratio

The Equity Ratio of Cell Biotech Co (049960.KQ) as of Nov 17, 2026 is 96.39 %. In the previous year, Equity Ratio was 95.22 % — a change of 1.22% (higher).

Equity Ratio

96.39 %

YoY

1.22%

Last updated:

Equity Ratio of Cell Biotech Co is 2025 96.39 % . Equity Ratio of Cell Biotech Co was 2024 95.22 % . It decreases by 1.22% higher compared to the previous year.

The Cell Biotech Co Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
94.27 KRW
Jan 1, 2019
95.66 KRW
Jan 1, 2020
94.95 KRW
Jan 1, 2021
94.52 KRW
Jan 1, 2022
93.31 KRW
Jan 1, 2023
95.11 KRW
Jan 1, 2024
95.22 KRW
Jan 1, 2025
96.39 KRW
The Cell Biotech Co Equity Ratio history
YEAREquity RatioYoY
96.39 %+1.22%
95.22 %+0.12%
95.11 %+1.92%
93.31 %-1.27%
94.52 %-0.46%
94.95 %-0.74%
95.66 %+1.48%
94.27 %+0.83%
93.49 %+0.57%
92.96 %+1.35%
91.72 %+0.90%
90.90 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Biotech Co Stock analysis

What does Cell Biotech Co do? Cell Biotech Co., Ltd. generates revenue through the production and sale of probiotic lactobacillus products. The company manufactures lactic acid bacteria (LAB) powders, which serve as raw materials for foods and medicines targeting immunization enhancement and digestion improvement. Finished products containing LABs are sold for intestinal health improvement, carcinogen inhibition, and calcium supplementation, distributed domestically and internationally. The firm focuses on functional health applications within the probiotics market. The company's primary customers are domestic and international food and pharmaceutical manufacturers seeking functional ingredients, as well as end consumers purchasing finished probiotic products. LAB powders are supplied to food and medicine producers, while finished products reach consumers directly for health benefits. Distribution channels include both local and global markets, emphasizing the functional health segments of the industry. Cell Biotech's product portfolio centers on LAB-based solutions for health enhancement, with no additional brands or external partnerships mentioned in the business description. The company operates solely within the probiotics sector, leveraging its research and development capabilities to create products aligned with digestive and immune health needs. Cell Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Biotech Co stock

Equity Ratio of Cell Biotech Co is 96.39 % in 2025.

Equity Ratio of Cell Biotech Co changed from 95.22 % to 96.39 %, representing a 1.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Cell Biotech Co since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Cell Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cell Biotech Co

All Key Metrics — Cell Biotech Co